The treatment of advanced prostate cancer has rapidly evolved. Androgen deprivation therapy is recognized as the first-line therapy for metastatic disease; however, a substantial proportion of patients will eventually progress to develop castration-resistance. For the past several years, docetaxel-based chemotherapy has shown significant therapeutic benefit in castration-resistant prostate cancer. Over the last 5 years, several new agents such as the enzalutamide, abiraterone, cabazitaxel, and 223 radium have been developed which have all been associated with improved quality of life, pain palliation, and an increase in survival. Unfortunately, there are no Korean treatment guideline for metastatic prostate cancer and/or castration-resistant prostate cancer which has been developed based on adequate review and assessment of evidences. Thus, a guideline adequate for domestic circumstances is eagerly needed
. The definition of the level of recommendation and the level of evidence Definition Level of evidence I Level 1 or multiple level 2 study II One more level 2 or multiple level 3 study III One more level 3 or level 4 study IV One more level 5 or level 6 study Level of study 1 Systematic review, meta-analysis, randomized controlled trial 2
Nonrandomized controlled trial, cohort study 3
Case-control study 4 Case-series (single arm before-after study) 5 Cross-sectional study, case report 6 Expert opinion Level of recommendation A Based on clinical studies of good quality and consistency addressing the specific recommendations and including at least one randomised trial B
Based on well-conducted clinical studies, but without randomised clinical trials C Made despite the absence of directly applicable clinical studies of good quality 
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